Macular function after PDT in myopic maculopathy: Psychophysical and electrophysiological evaluation

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 4, 2005, Pages 1453-1462

  Varano, Monica ^a   Parisi, Vincenzo ^a   Tedeschi, Massimiliano ^a   Sciamanna, Marta ^a   Gallinaro, Geltrude ^a   Capaldo, Nicoletta ^a   Catalano, Susanna ^b   Pascarella, Antonella ^b  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b Ospedale Oftalmico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; DIAGNOSTIC AGENT; PHOTOSENSITIZING AGENT; PORPHYRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MYOPIA; PERIMETRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RETINA MACULA LUTEA; RETINA MACULOPATHY; SCANNING LASER OPHTHALMOSCOPY; STATISTICAL ANALYSIS; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; DEGENERATIVE MYOPIA; FLUORESCENCE ANGIOGRAPHY; LASER; MIDDLE AGED; OPHTHALMOSCOPY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY;

ADULT; AGED; CHOROIDAL NEOVASCULARIZATION; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; LASERS; MACULA LUTEA; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; OPHTHALMOSCOPY; PERIMETRY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; VISUAL ACUITY;

EID: 18244362095     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0903     Document Type: Article

References (40)

1. Tabandeh HT, Flynn HW, Scott IU, et al. VA outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology. 1999;106:2063-2067.
2. Fleury I, De Laey JJ. Prognosis of the disciform response in high myopia. Bull Soc Belge Ophthalmol. 1983;206:91-102.
3. Secrétan M, Kuhn D, Soubrane G, Coscas GJ. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7:307-316.
4. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241-12444.
5. Hampton RG, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology. 1983;90:923-926.
6. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91:177-183.
7. Soubrane G, Pisan J, Bornert P, Perrenoud F, Coscas G. Néovaisseaux sous-rétiniens de la myopie dégé nérative: rèsultats de la photocoagulation. Bull Soc Ophtalmol Fr. 1986;86:269-272.
8. Deutman AF, Hendikse F, Hoyng C. Traitement des néovaisseaux sous-rétiniens dans la myopie dégénérative. Ophthalmologie. 1989;3:299-301.
9. Thomas MA, Dickinson JD, Melberg NS, et al. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994;101:1384-1396.
10. Adelberg DA, Del Priore LV, Kaplan HJ. Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina. 1995;15:198-205.
11. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. TAP Report 1. Arch Ophthalmol. 1999;117:1329-1345.
12. TAP Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol. 2001;119:198-207.
13. Blinder KJ, Bradley S, Bressler NM, et al. Effect on lesion size, VA, and lesion composition on VA change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no 1. Am J Ophthalmol. 2003;136:407-418.
14. VIP Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia with Verteporfin: one-year results of a randomised clinical trials. VIP report 1. Ophthalmology. 2001;108:841-852.
15. TAP and VIP Study Groups. Photodynamic therapy Of Subfoveal Choroidal Neovascularization with Verteporfin: fluorescein angiographic guidelines for evaluation and treatment. TAP and VIP report 2. Arch Ophthalmol. 2003;121:1253-1268.
16. VIP Study Group. Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia: 2-year results of a randomized clinical trial. VIP report No 3. Ophthalmology. 2003;110:667-673.
17. Montera JA, Ruiz-Morerto JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularization. Br J Ophthalmol. 2003;87:173-176.
18. Varano M, Scassa C. Scanning laser ophthalmoscope microperimetry. Semin Ophthalmol. 1998;13:203-209.
19. Rohrschneider K, Fendrich T, Becker M, et al. Static fundus perimetry using the scanning laser ophthalmoscope with an automated threshold strategy. Graefes Arch Clin Exp Ophthalmol. 1995;233:743-749.
20. Rohrschneider K, Becker M, Schumacher N, et al. Normal values for fundus perimetry with the scanning laser ophthalmoscope. Am J Ophthalmol. 1998;126:52-58.
21. Parisi V, Falsini B. Electrophysiological evaluation of the macular cone system: focal electroretinography and visual evoked potentials after photostress. Semin Ophthalmol. 1998;13:178-188.
22. Seiple WH, Siegel IM, Carr RE, Mayron C. Evaluating macular function using the focal ERG. Invest Ophthalmol Vis Sci. 1986;27:1123-1130.
23. Falsini B, Fadda A, Iarossi G, et al. Retinal sensitivity to flicker modulation: reduced by early age-related maculopathy. Invest Ophthalmol Vis Sci. 2000;41:1498-1506.
24. Miyake Y, Shiroyama N, Ota I, Horiguchi M. Local macular electroretinographic responses in idiopathic central serous chorioretinopathy. Am J Ophthalmol. 1988;106:546-550.
25. Iarossi G, Falsini B, Piccardi M. Regional cone dysfunction in retinitis pigmentosa evaluated by flicker ERGs: relationship with perimetric sensitivity losses. Invest Ophthalmol Vis Sci. 2003;44:866-874.
26. Parisi V, Canu D, Iarossi G, Olzi D, Falsini B. Altered recovery of macular function after bleaching in Stargardt's disease-fundus flavimaculatus: pattern VEP evidence. Invest Ophthalmol Vis Sci. 2002;43:2741-2748.
27. Porciatti V, Falsini B, Fadda A, Bolzani R. Steady-state analysis of the focal ERG to pattern and flicker: relationship between ERG components and retinal pathology. Clin Vis Sci. 1989;4:323-332.
28. Falsini B, Bardocci A, Porciatti V, Bolzani R, Piccardi M. Macular dysfunction in multiple sclerosis revealed by steady-state flicker and pattern ERGs. Electroencephalogr Clin Neurophysiol. 1992;82:53-59.
29. Parisi V, Pierelli F, Restuccia R, et al. VEP after photostress response in multiple sclerosis patients previously affected by optic neuritis. Electroencephalogr Clin Neurophysiol. 1998;108:73-79.
30. Fiorentini A, Maffei L, Pirchio M, et al. The ERG in response to alternating gratings in patients with diseases of the peripheral visual pathway. Invest Ophthalmol Vis Sci. 1981;21:490-493.
31. Parodi MB, Da Pozzo S, Ravalico G. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia. Br J Ophthalmol. 2003;87:177-183.
32. Grossniklaus HE, Gass JDM. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol. 1998;126:59-69.
33. Coscas G, Soubrane G. Choroidal neovascularisation in degenerativemyopia. In: Ryan SJ, ed. Retina (Italian version). Vol. 2. St. Louis: CV Mosby Co.; 1992;211-222.
34. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91:1573-1581.
35. Moschos MN, Panayotidis D, Moschos MM, et al. A preliminary assessment of macular function by MFERG in myopic eyes with CNV with complete response to photodynamic therapy. Eur J Ophthalmol. 2003;13:461-467.
36. Schmidt-Erfuth U, Laqua H, Schlotzer-Schrehardt U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835-844.
37. Schmidt-Erfurth U, Hasan T. Mechanism of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.
38. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;144:2147-2154.
39. Schmidt-Erfurth U, Michels S, Barbazzetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841.
40. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose related structural effects of photodynamic therapy oh choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748-757.